Pfizer's Beijing Research and Development Center opened in BioPark on March 29 in the Beijing Economic-Technological Development Area (Beijing E-Town).

This is Pfizer's third research and development center in China. Its establishment is a further deepening of Pfizer's research and development strategy in China and demonstrates the "E-Town Speed" in driving high-quality development of the biotechnology and health industries.

Pfizer's Beijing Research and Development Center will upgrade Pfizer's global innovative drug research layout in China, drive the efficient implementation of the China-All-In strategy and synchronize the early clinical and all key Phase III research of the companies global innovative drugs in China.

The center will play a leading role in Pfizer's innovative drug development in China. It will focus on leading clinical trial efficiency, accelerating the entire process from new drug clinical trial application to approval in China for global innovative drugs, collaborating to build a globally standardized Phase I clinical research institution and research capabilities, and nurturing high-end talent for global innovative drug development.

The pharmaceutical and health industry is a key industry focus in Beijing E-Town. E-Town has already gathered nearly 5,000 bio-pharmaceutical market entities, covering the entire industry chain of drugs, equipment, and services. The industry accounts for nearly half of the city's total scale, making it the most concentrated area for the development of the pharmaceutical and health industry in Beijing.